Global Patent Index - EP 2344168 A1

EP 2344168 A1 20110720 - ANTI-INFECTIVE FORMULATION AND METHODS OF USE

Title (en)

ANTI-INFECTIVE FORMULATION AND METHODS OF USE

Title (de)

ANTIINFEKTIÖSE FORMULIERUNG UND VERWENDUNGSVERFAHREN

Title (fr)

FORMULATION ANTI-INFECTION ET PROCÉDÉS D'UTILISATION CORRESPONDANTS

Publication

EP 2344168 A1 20110720 (EN)

Application

EP 09820801 A 20090915

Priority

  • NZ 2009000195 W 20090915
  • NZ 57134708 A 20080917

Abstract (en)

[origin: WO2010044679A1] A formulation, for administration to the teat canal or/and lower portion of teat cistern of a mammary gland of an animal, wherein the formulation prior to delivery is in the form of a paste, the formulation including: an oil-based physical barrier material which is able to form a cohesive mass in the teat canal and/or the lower portion of the teat cistern, and at least one antiseptic compound mixed with the barrier material.

IPC 8 full level

A61K 33/24 (2006.01); A61K 9/00 (2006.01); A61K 31/155 (2006.01); A61P 31/02 (2006.01)

CPC (source: EP)

A61K 9/0041 (2013.01); A61K 9/06 (2013.01); A61K 31/155 (2013.01); A61K 33/00 (2013.01); A61P 31/00 (2017.12); A61P 31/02 (2017.12)

Citation (third parties)

Third party : anonymous

  • GB 2273443 A 19940622 - BIMEDA RES DEV LTD [IE]
  • GB 2273441 A 19940622 - BIMEDA RES DEV LTD [IE]
  • A.J. BRADLEY: "A Study of the Anti-infective Properties of TeatSealTm Formulations in the Presence and Absence of Acriflavine", MJC-20 A STUDY OF THE ANTI-INFECTIVE PROPERTIES OFTEATSEAL FORMULATIONS, 13 February 2007 (2007-02-13), pages 1 - 6, XP055313936
  • MEANEY, W.J.: "Effect of a dry period teat seal on bovine udder infection", IRISH JOURNAL OF AGRICULTURAL RESEARCH, vol. 16, no. 3, December 1977 (1977-12-01), pages 293 - 299, XP055313937
  • JOHNSON, S. D.: "Observations on the treatment of mastitis with acriflavine", CORNELL VET., vol. 31, 1941, pages 127 - 148, XP055313939
  • STABLEFORTH, A. W. ET AL.: "Entrozon and Acriflavine for the treatment of chronic, contagious Bovine Mastitis", THE VETERINARY RECORD, vol. 50, no. 23, 4 June 1938 (1938-06-04), pages 663 - 676, XP055313941
  • GAVINI ET AL.: "Mucoadhesive vaginal tablets as veterinary delivery system for the controlled release of an antimicrobial drug acriflavine", AAPS PHARM SCI, vol. 3, no. 3, 26 September 2002 (2002-09-26), pages 1 - 7, XP055313943
  • DORLAND I. ET AL: "Dorlands Illustrated Medical Dictionary. 28th ed.", 1994, W.B. SAUNDERS, article "Definition of Acriflavine", pages: 19, XP055313944
  • CLARENCE FRASER: "The Merck Veterinary Manual. 7th ed.", 1991, MERCK & COMPANY, INCORPORATED, article "Definition of Acriflavine as antiseptic", pages: 1532, XP055313947
  • A. J. BRADLEY: "A study of the Anti-infective Properties of TeatSealTM Formulations in the Presence and Absence of Acriflavine", MJC-20 A STUDY OF THE ANTI-INFECTIVE PROPERTIES OFTEATSEAL FORMULATIONS, 13 February 2007 (2007-02-13), pages 1 - 6, XP055313936
  • MEANEY, W.J.: "Effect of a dry period teat seal on bovine udder infection", IRISH JOURNAL OF AGRICULTURAL RESEARCH, vol. 16, no. 3, December 1977 (1977-12-01), pages 293 - 299, XP055313937

Third party :

  • WO 9531180 A1 19951123 - BIMEDA RES DEV LTD [IE], et al
  • WO 9826759 A1 19980625 - BIMEDA RES DEV LTD [IE], et al
  • WO 2010065747 A2 20100610 - MERIAL LTD [US], et al
  • GB 1441747 A 19760707 - LAZONBY B
  • CRISPIE F. ET AL: "The lantibiotic lacticin 3147 produced in a milk-based medium improves the efficacy of a bismuth-based teat seal in cattle deliberately infected with Staphylococcus aureus", JOURNAL OF DAIRY RESEARCH, vol. 72, no. 2, 1 May 2005 (2005-05-01), pages 159 - 167, XP009139355
  • LAPOLLA W.J. ET AL: "Topical Antibiotic Trends from 1993 to 2007: Use of Topical Antibiotics for Non-Evidence-Based Indications", DERMATOLOGIC SURGERY, vol. 37, no. 10, 2 September 2011 (2011-09-02), pages 1427 - 1433, XP055096263
  • BERCY P. ET AL: "Susceptibility to Various Oral Antiseptics of Porphyromonas gingivalis W83 Within a Biofilm", ADVANCES IN THERAPY, vol. 24, no. 6, November 2007 (2007-11-01), pages 1181 - 1191, XP055096264
  • GREEN K.D. ET AL: "Identification and Characterization of Inhibitors of the Aminoglycoside Resistance Acetyltransferase Eis from Mycobacterium tuberculosis", CHEMMEDCHEM, vol. 7, 5 September 2011 (2011-09-05), pages 73 - 77, XP055096266
  • SURVEYOR N. ET AL: "THE ACTION OF BETA-NAPHTHOL AND BISMUTH SUBNITRATE AS INTESTINAL ANTISEPTICS.", BR MED J, 14 December 1895 (1895-12-14), pages 1483 - 1485, XP055096270
  • DOMENICO P. ET AL: "Enhancement of Bismuth Antibacterila Activity with Lipophilic Thiol Chelators", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 41, no. 8, 1 August 1997 (1997-08-01), pages 1697 - 1703, XP002262341
  • WHITEHEAD M.W. ET AL: "Double-Blind Comparison of Absorbable Colloidal Bismuth Subcitrate and Nonabsorbable Bismuth Subnitrate in the Eradication of Helicobacter pylori and the Relief of Nonulcer Dyspepsia", HELICOBATER, vol. 5, no. 3, 2000, pages 169 - 175, XP055096311
  • NEWTON H.T. ET AL: "Comparison of the efficacy of cloxacillin alone and cloxacillin combined with aninternal teat sealant for dry-cow therapy", VETERINARY RECORD, vol. 162, 2008, pages 678 - 683, XP003033028

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

Designated extension state (EPC)

AL BA RS

DOCDB simple family (publication)

WO 2010044679 A1 20100422; AU 2009304000 A1 20100422; AU 2009304000 B2 20150806; AU 2009304000 C1 20220428; BR PI0918662 A2 20151201; CN 102159221 A 20110817; EP 2344168 A1 20110720; EP 2344168 A4 20140521; EP 2893932 A1 20150715; NZ 571347 A 20100430; ZA 201102857 B 20120926

DOCDB simple family (application)

NZ 2009000195 W 20090915; AU 2009304000 A 20090915; BR PI0918662 A 20090915; CN 200980136202 A 20090915; EP 09820801 A 20090915; EP 14196825 A 20090915; NZ 57134708 A 20080917; ZA 201102857 A 20110415